A Randomized Phase II Trial of a Preparative Regimen of Bortezomib, High Dose Melphalan, Arsenic Trioxide and Ascorbic Acid

BACKGROUND: Bortezomib is active for newly diagnosed and relapsed multiple myeloma, and has synergistic activity with melphalan. We conducted a randomized trial to determine the safety and efficacy of adding bortezomib to a preparative regimen of arsenic trioxide (ATO), ascorbic acid (AA) and melpha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sharma, Manish, Khan, Hassan, Thall, Peter F, Orlowski, Robert Z, Bassett, Roland L, Shah, Nina, Bashir, Qaiser, Parmar, Simrit, Wang, Michael, Shah, Jatin J, Hosing, Chitra M, Popat, Uday R, Giralt, Sergio A, Champlin, Richard E, Qazilbash, Muzaffar H
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015116/
https://ncbi.nlm.nih.gov/pubmed/21887685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26517
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados